Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study.

Healy DG, Falchi M, O'Sullivan SS, Bonifati V, Durr A, Bressman S, Brice A, Aasly J, Zabetian CP, Goldwurm S, Ferreira JJ, Tolosa E, Kay DM, Klein C, Williams DR, Marras C, Lang AE, Wszolek ZK, Berciano J, Schapira AH, Lynch T, Bhatia KP, Gasser T, Lees AJ, Wood NW, International LRRK2 Consortium. · 2008

Read Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. by Healy DG, Falchi M, O'Sullivan SS, Bonifati V, Durr A, Bressman S, Brice A, Aasly J, Zabetian CP, Goldwurm S, Ferreira JJ, Tolosa E, Kay DM, Klein C, Williams DR, Marras C, Lang AE, Wszolek ZK, Berciano J, Schapira AH, Lynch T, Bhatia KP, Gasser T, Lees AJ, Wood NW, International LRRK2 Consortium. (2008) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc2832754.txt.

Introduction

Healy and colleagues, for the International LRRK2 Consortium, pooled worldwide data in 2008 on Parkinson disease caused by faults in the LRRK2 gene. Twenty-one centers joined to answer three questions: how the inherited form looks, which gene changes truly cause disease, and how likely carriers are to fall ill. Risk figures came from over a thousand mutation carriers in one hundred thirty-three families.

Six mutations passed the bar as proven causes. The commonest, called Gly2019Ser, appeared in one percent of lone cases and four percent of family cases, peaking in the Middle East. A carrier's risk of Parkinson disease reached about twenty-eight percent by age fifty-nine and seventy-four percent by seventy-nine. Symptoms ran milder than in ordinary Parkinson disease.

Catalog record

CREATORHealy DG, Falchi M, O'Sullivan SS, Bonifati V, Durr A, Bressman S, Brice A, Aasly J, Zabetian CP, Goldwurm S, Ferreira JJ, Tolosa E, Kay DM, Klein C, Williams DR, Marras C, Lang AE, Wszolek ZK, Berciano J, Schapira AH, Lynch T, Bhatia KP, Gasser T, Lees AJ, Wood NW, International LRRK2 Consortium.
YEAR2008
COLLECTIONPAPERS
FORMATTXT
FILE SIZE45 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC2832754

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study By Daniel G Healy, Mario Falchi, Sean S O'Sullivan, Vincenzo Bonifati, Alexandra Durr, Susan Bressman, Alexis Brice, Jan Aasly, Cyrus P Zabetian, Stefano Goldwurm, Joaquim J Ferreira, Eduardo Tolosa Published in: The Lancet. Neurology DOI: 10.1016/S1474-4422(08)70117-0 ABSTRACT Summary Background Mutations in LRRK2, the gene that encodes leucine-rich repeat kinase 2, are a cause of Parkinson's disease (PD). The International LRRK2 Consortium was established to answer three key clinical questions: can LRRK2-associated PD be distinguished from idiopathic PD; which mutations in LRRK2 are pathogenic; and what is the age-specific cumulative risk of PD for individuals who inherit or are at risk of inheriting a deleterious mutation in LRRK2? Methods Researchers from 21 centres across the world collaborated on this study. The frequency of the common LRRK2 Gly2019Ser mutation was estimated on the basis of data from 24 populations worldwide, and the penetrance of the mutation was defined in 1045 people with mutations in LRRK2 from 133 families. The LRRK2 phenotype was defined on the basis of 59 motor and non-motor symptoms in 356 patients with LRRK2-associated PD and compared with the symptoms of 543 patients with pathologically proven idiopathic PD. Findings Six mutations met the consortium's criteria for being proven pathogenic. The frequency of the common LRRK2 Gly2019Ser mutation was 1% of patients with sporadic PD and 4% of patients with hereditary PD; the frequency was highest in the middle east and higher in southern Europe than in northern Europe. The risk of PD for a person who inherits the LRRK2 Gly2019Ser mutation was 28% at age 59 years, 51% at 69 years, and 74% at 79 years. The motor symptoms (eg, disease severity, rate of progression, occurrence of falls, and dyskinesia) and non-motor symptoms (eg, cognition and olfaction) of LRRK2-associated PD were more benign than those of idiopathic PD. Interpretation Mutations in LRRK2 are a clinically relevant cause of PD that merit testing in patients with hereditary PD and in subgroups of patients with PD. However, this knowledge should be applied with caution in the diagnosis and counselling of patients. Funding UK Medical Research Council; UK Parkinson's Disease Society; UK Brain Research Trust; Internationaal Parkinson Fonds; Volkswagen Foundation; National Institutes of Health: National Institute of Neurological Disorders and Stroke and National Institute of Aging; Udall Parkinson's Disease Centre of Excellence; Pacific Alzheimer Research Foundation Centre; Italian Telethon Foundation; Fondazione Grigioni per il Morbo di Parkinson; Michael J Fox Foundation for Parkinson's Research; Safra Global Genetics Consortium; US Department of Veterans Affairs; French Agence Nationale de la Recherche. INTRODUCTION Parkinson's disease (PD) affects 1–2% of people older than 65 years. Respective mutations in five genes—SNCA (α-synuclein), PARK2 (parkin), PARK7 (DJ-1), PINK1, and LRRK2—can cause parkinsonism that resembles idiopathic PD.1 LRRK2 encodes the 51-exon, multidomain protein, leucine-rich repeat kinase 2 (LRRK2); mutations in LRRK2 cause an autosomal dominant PD that, in most patients, produces a α-synuclein-type neuropathology.2, 3, 4 Although individual LRRK2 genotype–phenotype correlations have been reported,5, 6, 7 these have been reported for a mean of only five mutation carriers per study, and the results can not be easily compared because of the use of different clinical approaches, sample sizes, diagnostic criteria, and genotyping techniques. The International LRRK2 Consortium was established to pool worldwide data to answer important clinical questions through collective experience and research. Three questions have been considered by the consortium: can LRRK2-associated PD be distinguished from idiopathic PD; which mutations in LRRK2 are pathogenic; and what is the age-specific cumulative risk of PD for individuals who inherit or are at risk of inheriting a deleterious mutation in LRRK2? METHODS Patients and procedures Researchers at 21 primary centres collaborated on this study. The clinical and genetic data were collected and analysed at The National Hospital for Neurology and Neurosurgery, Queen Square, London, UK. The study was approved by the joint Research Ethics Committee of the Institute of Neurology and the National Hospital for Neurology and Neurosurgery, London, UK. Informed consent was obtained from each patient by the local ethics committees. Clinical data were collected at each participating centre on a standardised, two-part pro forma questionnaire. Each patient was assessed by a neurologist who was a specialist in movement disorders, and a separate pro forma was completed for each patient. The average time to complete the pro forma was 21 mins per patient. Most of the clinical data were collected prospectively and not specifically for this project. The first part of the pro forma consisted of 13 sections that focused on population demographics and genotyping techniques for the patients and controls. Each centre provided details on the number of patients with PD who were screened for mutations in LRRK2, their ethnic backgrounds, and the number of controls used, to confirm the pathogenicity of novel mutations. The second part of the pro forma was a 59-section clinical questionnaire on motor and non-motor symptoms. The pro formas were completed by the neurologist. Validated scales were used to assess olfaction (University of Pennsylvania smell identification test [UPSIT]),8 cognition (the mini-mental state examination),9 and to stage the disease and its progression (the Hoehn and Yahr scale10). We attempted to assess the severity of other symptoms, such as anxiety, depression, sleep disturbance, dysautonomia, and dystonia, with unified standardised criteria; however, this was difficult to standardise across centres, and instead we chose a simplified “symptom present”, “symptom absent”, or “symptom not recorded” scoring method because it was more reproducible. The rate of disease progression was measured by the time taken to reach each stage on the Hoehn and Yahr scale and the percentage of patients at each stage of the scale with PD for longer than 10 years, starting from symptom onset rather than time of diagnosis. The clinical features of mutations in LRRK2-associated PD were compared with a series of 543 clinically documented, pathologically proven cases of idiopathic PD from the Queen Square Brain Bank (QSBB). All QSBB patients were screened for the LRRK2 Gly2019Ser mutation, and carriers were excluded. The same phenotyping methods were used for patients with mutations in LRRK2 as were used in the QSBB group. Mutation-screening methods were not standardised; however, most centres used direct DNA sequencing, and we relied on the quality controls at each participating centre. Mutations were arbitrarily designated as ‘proven’ pathogenic if they were found in three or more unrelated participants, or if the mutation segregated within a large family with many members who had PD and was not found in more than 1000 ethnically matched controls. The consortium acknowledges that many reported mutations do not fulfil these criteria but are likely to be pathogenic. Statistical analysis The penetrance of all mutations in LRRK2 (age-specific cumulative risk of PD) was estimated with the Kaplan-Meier life table survival method and maximum-likelihood estimates calculated with the pedigree analysis package for Java (jPAP Version 1.5.0).11, 12 Kaplan-Meier survival function was calculated for mutation carriers and individuals whose probability of carrying a mutation was greater than 90% (as inferred from jPAP) in affected and unaffected individuals.13 No minimum size was imposed on families (ie, the analysis was not restricted to large families with many affected [penetrating] members). To further minimise any ascertainment bias, the index case of each

Read the complete text